Klitenic Samantha B, Levan Macey L, Van Pilsum Rasmussen Sarah E, Durand Christine M
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD USA.
Department of Medicine and Oncology, Johns Hopkins University School of Medicine, 725 North Wolfe Street/PCTB 228, Baltimore, MD 21205 USA.
Curr Transplant Rep. 2021;8(4):314-323. doi: 10.1007/s40472-021-00345-y. Epub 2021 Nov 18.
The HIV Organ Policy Equity (HOPE) Act permits transplantation from donors-with-HIV to recipients-with-HIV (HIV D + /R +). We assess HOPE implementation, summarizing progress and challenges at clinical, legislative, and community levels.
As of July 2021, there have been 300 kidney and 87 liver transplants within HOPE research studies in the USA. Early HIV D + /R + kidney transplant outcomes show excellent patient survival (100%) and graft survival (92%). The number of HOPE donors continues to grow annually but remains lower than projections. State-level policy restrictions are identified in 34 states; however, these do not seem to have impacted practice; 16 states have passed new legislation to facilitate HIV D + /R + transplantation. Stigma related to HIV and low donor registration rates pose additional barriers.
Early outcomes of HOPE Act transplants are encouraging. Progress to reach full implementation and realize the full benefit of this innovation is ongoing.
《HIV器官政策公平性(HOPE)法案》允许将来自HIV感染者的器官移植给HIV感染者(HIV供体+/受体+)。我们评估HOPE法案的实施情况,总结临床、立法和社区层面的进展与挑战。
截至2021年7月,美国HOPE研究项目中已进行了300例肾移植和87例肝移植。早期HIV供体+/受体+肾移植结果显示患者生存率极佳(100%),移植物生存率也很高(92%)。HOPE供体数量每年持续增长,但仍低于预期。34个州存在州级政策限制;然而,这些似乎并未影响实际操作;16个州已通过新立法以促进HIV供体+/受体+移植。与HIV相关的污名以及较低的供体登记率构成了额外障碍。
HOPE法案移植的早期结果令人鼓舞。为全面实施并充分实现这一创新的益处,相关工作正在持续推进。